Basal cell carcinoma (BCC), the most common type of cancer, is characterized by aberrant Hedgehog (Hh) pathway activity. Mutations in pathway components, such as PATCHED1 (PTCH1), are commonly found in BCC. While the tumor suppressor role of PTCH1 in BCC is well established, how Hh pathway activation disrupts normal skin homeostasis to promote BCC formation remains poorly understood. Like Ptc1, Sufu is a major negative regulator of the Hh pathway. Previously, we showed that inactivation of Sufu in the skin does not result in BCC formation. Why loss of Ptc1, but not Sufu, in the epidermis induces BCC formation is unclear. In this report, we utilized gene expression profiling to identify biological pathways and processes that distinguish Sufu from Ptc1 mutants, and discovered a novel role for Sufu in cell cycle regulation. We demonstrated that the Hh pathway activation in Sufu and Ptc1 mutant skin is associated with abnormal cell cycle entry, ectopic expression of D-type cyclins and increased DNA damage. However, despite the presence of DNA damage, p53 stabilization was impaired in the mutant skin. Alternative mechanism to halt genomic instability is the activation of G 2 /M cell cycle checkpoint, which can occur independent of p53. We found that while Ptc1 mutant cells continue to cycle, which would favor genomic instability, loss of Sufu results in G 2 /M cell cycle arrest. This finding may explain why inactivation of Sufu is not sufficient to drive BCC formation. Taken together, these studies revealed a unique role for Sufu in G 2 /M phase progression, and uncovered the molecular and cellular features associated with Hh-driven BCC.
INTRODUCTION
Basal cell carcinoma (BCC) of the skin, the most common human malignancies, is characterized by genomic instability, 1,2 TP53 mutations 3 and the Hedgehog (Hh) pathway activation. 4, 5 Mutations in PATCHED1 (PTCH1), which encodes the Hh-binding receptor and a major negative regulator of the pathway, are the predominant genetic alteration found in human BCC. Consistent with this, inactivation of Ptc1 (the mouse counterpart) in the mouse skin results in BCC formation. [6] [7] [8] Ptc1 acts negatively by inhibiting the activity of Smoothened. Activation of Smoothened promotes the dissociation of inhibitory Sufu-Gli complexes, allowing Gli transcription factors to translocate into the nucleus for Hh target gene expression. [9] [10] [11] Among the three Gli proteins, Gli2 is the major mediator of Hh response in the skin, 12 and overexpression of Gli1 or Gli2 in the epidermis induces BCC formation. 13, 14 While it is well established that abnormal Hh pathway activation leads to BCC, the downstream molecular event(s) that lead to epidermal transformation are largely unknown.
Several studies indicated that Hh signaling impinges on the cell cycle machinery to promote G 1 /S transition and to inhibit cell cycle withdrawal. Genetic studies in mice revealed that Hh is a potent mitogen, promoting the expression of cell cycle regulators (D-type cyclins, N-myc and E2Fs) during cerebellar 12, [15] [16] [17] and skin development. 12, 15 Hh signaling induces the degradation of the tumor suppressor p53 in mouse embryonic fibroblasts 18 and can override differentiation-induced signals for cell cycle arrest in cultured human keratinocytes. 19 These in vitro studies suggest that Hh signaling drives tumorigenesis via evasion of p53 tumor surveillance and cell cycle arrest, however, their physiological relevance remains undefined.
Like Ptc1, Sufu is a major negative regulator of the Hh pathway. Sufu À / À mice exhibit ectopic Hh pathway activation, and display neural and cardiac defects similar to those of Ptc1 À / À mice. [20] [21] [22] However, SUFU mutations are rare in human BCC and often accompanied by PTCH1 and/or TP53 mutations, 3, 23 suggesting that SUFU mutations might have different impact from PTCH1 mutations in BCC tumorigenesis. Consistent with this, we recently showed that inactivation of Sufu in the mouse skin does not result in BCC formation. 11 In this study, we demonstrated that Hh pathway activation leads to similar molecular defects, including increased D-type cyclin expression, sustained G 1 /S progression and elevated DNA damage. We utilized the distinction between Ptc1 and Sufu knock out (KO) keratinocytes in their susceptibility to undergo transformation, and performed comparative transcriptome analysis to identify molecular events critical for BCC formation. By Gene Set Enrichment Analysis, we uncovered molecular pathways that are characteristic of Sufu and distinct from Ptc1 mutants, including those involved in DNA repair, chromosomal maintenance and mitosis, suggesting that Sufu has a unique role in cell cycle regulation. Consistent with this prediction, we showed that Sufu, but not Ptc1, KO keratinocytes exhibit a cell cycle arrest at G 2 /M, thus halting tumor progression. Loss of G 2 /M checkpoint renders p53 response critical for tumor suppression. Interestingly, we found that DNA damage-mediated p53 stabilization is uncoupled in these mutants. Together, these results uncover the importance of p53-mediated response and G 2 /M checkpoint as critical barriers for Hh-driven BCC.
RESULTS AND DISCUSSION
Epidermal inactivation of Sufu and Ptc1 leads to similar embryonic skin defects We previously reported that skin from epidermis-specific deletion of Ptc1, but not Sufu, embryos grafted onto the backs of nude mice developed BCC, suggesting that additional genetic alterations are required to transform Sufu-mutant cells into BCC. 11 The function of Ptc1 in BCC formation has been extensively examined. 6, [24] [25] [26] [27] To gain insight into the early events of malignancy, we compared the embryonic skin phenotypes of Sufu and Ptc1 mutants. Histological staining revealed strikingly similar epidermal defects between Sufu and Ptc1 mutants at E18.5, which include a reduction in the number of hair follicles (arrows in Figures 1a-c) . Both Sufu and Ptc1 mutants displayed compromised epidermal differentiation (Supplementary Figures S1a-f) and ectopic expression of Hh target genes, Gli1 and Ptc1, in the interfollicular epidermis (arrows in Figures 1d-i) . It has been suggested that a critical threshold of Hh pathway activity is required to induce BCC formation. 28 To determine whether there is a difference in the extent of pathway activation in Sufu and Ptc1 mutant skin, we performed quantitative RT-PCR analysis on keratinocytes isolated from both mutants. Although differential expression of Gli2 and Gli3 proteins was found in Sufu and Ptc1 KO keratinocytes ( Supplementary  Figures S2a-c) , Hh target genes, Gli1 and Ptc2, were upregulated to a similar extent in Sufu and Ptc1 KO keratinocytes compared with control keratinocytes (Supplementary Figure S2d) . Furthermore, Sufu and Ptc1 mutant skin displayed a three-fold increase in actively cycling cells, as revealed by Ki-67 staining compared with the control (Figures 1j-l and p ). These results demonstrate that despite the differential role of Sufu and Ptc1 in the postnatal skin, Sufu and Ptc1 have similar roles in embryonic skin development: they are required for the formation of hair follicles, and control proliferation and differentiation of the interfollicular epidermis.
Loss of Sufu and Ptc1 results in aberrant cell cycle progression Sustained progression through the cell cycle is a hallmark of tumor cells. To determine what drives the increase in proliferation, we examined the expression of the key regulatory molecules involved in cell cycle entry, particularly D-type cyclins. Human BCC and mouse BCC models exhibit upregulation of cyclins D1 and D2, suggesting that expression of D-type cyclins contributes to tumor growth. 28 Immunohistochemistry using an antibody that recognizes both cyclins D1 and D2 revealed ectopic expression in the interfollicular epidermis of Sufu and Ptc1 mutant skin compared with the control (Figures 1m-o and q) . Consistent with this, western blot analysis revealed a two-fold increase in cyclins D1/2 protein level in Sufu and Ptc1 KO keratinocytes compared with the control (Figure 1r ). These findings are consistent with previous reports demonstrating that Hh signaling promotes the expression of D-type cyclins, 12, 16 and suggest that the increased proliferation observed in Sufu and Ptc1 mutants is attributed to aberrant expression of D-type cyclins.
Identification of biological pathways and processes discriminating Ptc1 from Sufu mutants Our analysis thus far has revealed biological processes that are similar between Ptc1 and Sufu mutants. To identify the molecular difference between Sufu and Ptc1 mutants, we performed microarray analysis on Sufu and Ptc1 KO keratinocytes coupled with Gene Set Enrichment Analysis, a computational method used to identify over-represented biological pathways and processes. 29 Significant gene sets (FDR o0.05, Po0.01) were visualized as interaction networks with Cytoscape and Enrichment Map. 30 From this stringent cutoff, we identified distinct and overlapping biological pathways that are characteristic of Sufu and Ptc1 KO keratinocytes. Overlapping gene sets between Sufu and Ptc1 mutants include those involved in sensory perception and neurotransmission (Supplementary Figure S3 and Supplementary  Table 1) , and their significance remains to be investigated. In this study, we focused on gene sets that are unique in Sufu KO keratinocytes compared with Ptc1 KO keratinocytes.
We identified 13 gene sets that were significantly enriched in Sufu KO keratinocytes, whereby 11 of these are implicated in cell cycle control (Figure 2a) . Specifically, Sufu KO keratinocytes were characterized by genes involved in chromosome maintenance (Zwilch, Sgol1 and Kif23), mitosis (CyclinB1, CenpE and Mad2) and DNA repair (Fancd2, Smc2 and Cercr2) (Figure 2b, Supplementary Table 2 ). DNA repair pathways are intimately associated with the cell cycle, as DNA lesions typically trigger cell cycle arrest. These results suggest that Sufu has a unique function in cell cycle regulation.
We uncovered 35 gene sets that were significantly enriched in Ptc1 KO keratinocytes and over 50% of these are involved in transforming growth factor-b signaling, as well as extracellular matrix remodeling and collagen metabolic processes ( Figure 2a ). Genes associated with extracellular matrix destruction and cell migration (Mmp3, Mmp10, Slit3, Vcan and Adamts6) and genes involved in transforming growth factor-b pathway (Smad7, Tgfb, Tmp4 and Acvr1b) were enriched in Ptc1 KO keratinocytes ( Figure 2b ). We speculate that these biological events would favor invasion of tumor cells into surrounding stroma during BCC formation. The functional processes characterized by Ptc1 KO keratinocytes have some overlap with those found in previously published transcriptomes derived from human BCC. This includes genes associated with cell mobility, collagen metabolism/ anabolism and extracellular matrix processing. [31] [32] [33] Although the transforming growth factor-b signaling pathway was not uncovered from human BCC microarray analysis, members of the transforming growth factor-b family were significantly upregulated at both the mRNA and protein levels in human skin tumors including BCC. 34, 35 In general, there is a low level of gene overlap between human BCC samples. The biological groups that reoccur in published human BCC studies are enriched in processes involved in enzymatic activity and structure/adhesion. 36 Therefore, our comparative analysis between Ptc1 and Sufu KO keratinocytes here is informative, unveiling the major molecular pathways involved in BCC pathogenesis. Importantly, the unique cell cycle pathway signature in Sufu KO keratinocytes suggests that the difference in the tumorigenic potential of Sufu and Ptc1 mutants could be attributed to their distinct response(s) in cell cycle regulation.
Activation of G 2 /M checkpoint in Sufu mutants To determine whether Sufu has a specific role in cell cycle regulation, we examined the distribution of cells in G 0 /G 1 , S and G 2 /M phases of the cell cycle in Sufu KO keratinocytes. Flow cytometric analysis of the DNA content of Sufu KO keratinocytes revealed a similar cell cycle profile as Ptc1 KO keratinocytes, both showing a significant enrichment in the G 2 /M phase (Figure 3a) . Accumulation of cells in the G 2 /M phase may reflect increased cells at G 2 phase (G 2 /M checkpoint) or M phase (mitotic cells). To distinguish between these possibilities, we evaluated the mitotic index in Sufu-mutant skin and keratinocytes, and found similar mitotic count as the control. In contrast, a significant increase in mitotic cells was found in Ptc1-mutant skin (Figures 3b-g and k) . A higher proportion of mitotic cells found in Ptc1 mutants indicates that loss of Ptc1 leads to increased proportion of cells at M phase, which is consistent with previous finding that Ptc1 inhibits the G 2 /M phase transition. 6, 37 To determine whether Sufu KO keratinocytes exhibit a G 2 /M checkpoint cell cycle arrest, we examined the expression and activity of a mitosis-promoting complex, cyclin B1-cyclin-dependent kinase 1. Immunohistochemistry revealed elevated cyclin B1-positive cells in Sufu-and Ptc1-mutant skin compared with the control (Figures 3h-j and l) . This may explain the enrichment of G 2 /M phase observed by flow cytometry (Figure 3a) . Although the number of cyclin B1-positive cells increased in Ptc1 mutants, their level of expression was reduced compared with Sufu and control skin. In agreement with this finding, a modest, but significant, upregulation in the level of cyclin B1 protein was observed in Sufu KO keratinocytes, whereas Ptc1 KO keratinocytes did not exhibit a significant change when compared with the control (Figure 3m) . Interestingly, Sufu and Ptc1 mutants displayed differential subcellular localization of cyclin B1 ( Figure 3l ). As nuclear localization of cyclin B1 is a feature of mitotic cells (reviewed in Takizawa et al. Cell cycle control Graphic representation of cdk1-p/total cdk1, data are given as means ± s.e.m. of n43 for control, n ¼ 4 for Sufu KO keratinocytes and n ¼ 3 for Ptc1 KO keratinocytes (*Po0.05, one-way ANOVA).
findings reveal that loss of Sufu results in G 2 cell cycle arrest, thereby restraining tumorigenesis and offers an explanation as to why inactivation of Sufu is insufficient to induce BCC formation.
Uncoupling of DNA damage and p53 response in Sufu-and Ptc1-mutant skin Cell cycle arrest at G 2 is typically elicited in response to DNA damage. Previous studies have demonstrated that oncogeneinduced aberrant cell-division cycles, such as overexpression of S-phase-promoting oncogenes, trigger cellular DNA replication stress and DNA damage. 39, 40 We found that Sufu-and Ptc1-mutant skin display expanded expression of PCNA, a marker most highly expressed during S-phase, compared with the control (Figures 4a-c) . This increase of cell proliferation is associated with the appearance of DNA damage, as revealed by gH2AX staining, in Sufu and Ptc1 mutants (Figures 4d-f) . No DNA lesions were detected in the control skin. DNA damage triggers a series of cellular cascades, leading to cell cycle arrest, DNA repair or apoptosis. These events require the tumor suppressor protein, p53, which turns over rapidly under normal conditions, but becomes stabilized and activated in response to DNA damage. Strikingly, p53 protein expression was undetectable in Sufu and Ptc1 mutants, despite the presence of DNA damage (Figures 4g-i) . Indeed, p53 RNA expression was reduced by B20% in both Sufu and Ptc1 KO keratinocytes (Figure 4j ). Consistent with this downregulation of p53 level, Sufu and Ptc1 KO keratinocytes displayed reduced expression of p53-responsive genes, p21 and mdm2 (Figure 4k ). These observations provide in vivo evidence that Hh pathway activation suppresses p53 accumulation, as revealed previously in mouse embryonic fibroblasts. 18 To exclude the possibility that the skin is a unique system, whereby response to DNA damage is independent of p53, Sufu and Ptc1 mutant embryos were exposed to ionizing radiation. Ionizing radiation induced the appearance of gH2AX-positive cells, accumulation of p53 protein, and p21 expression in Sufu-and Ptc1-mutant skin that is comparable to control (Supplementary Figure 4) . While we cannot exclude the possibilities that cell cycle-driven and ionizing radiation-induced DNA damages elicit distinct (p53-dependent or -independent) responses, these data suggest that p53 can be induced by DNA damage in the skin. Taken together, these results indicate that both loss of Sufu and Ptc1 impair p53 response to cell cycle-driven DNA damage.
In retinal neural progenitors, inactivation of Sufu leads to altered cell cycle kinetics and proliferation, 41 suggesting that Sufu regulates the cell cycle. In this study, we demonstrate that loss of Sufu in keratinocytes results in G 2 /M cell cycle arrest. This is critical for tumor suppression, especially as Hh pathway activation abrogates p53 response. It remains unclear whether the cell cycle effect in Sufu mutants is Gli-dependent or -independent. For example, it is possible that differential expression of Gli proteins in Sufu and Ptc1 mutants (Supplementary Figure S2 ) accounts for the difference in tumor potential. However, based on our findings here, we favor the notion that cyclin B1 regulation by The Hh pathway activation triggers aberrant cell cycle progression (that is, increase D-type cyclin expression), which leads to replication stress and DNA damage. DNA damage triggers p53 accumulation and activation, as well as DNA damage response that results in G 2 /M cell cycle arrest. Impairment or escape from p53-mediated tumor surveillance system favors genetic instability and tumorigenesis. Therefore, the Hh pathway activation promotes tumorigenesis via two distinct mechanisms (1) suppression of p53 accumulation and (2) sustained Sufu-dependent G 2 /M progression.
Ptc1 and unknown cell cycle regulators controlled by Sufu are the key mechanisms for this difference. Comparing Sufu mutants to other Hh-driven BCC models, such as skin-specific overexpression of Gli2 or oncogenic Smoothened, may be able to shed light into the potential mechanism.
In conclusion, using genetic and biochemical approaches, we identified and characterized the molecular events involved in BCC pathogenesis using a comparative analysis between Ptc1 and Sufu mutants. Our data indicate that Hh pathway activation induces tumorigenesis by evasion of p53-mediated tumor-suppressive activity and G 2 /M cell cycle checkpoints (Figure 4l) . We uncovered here a novel role for Sufu in cell cycle regulation, which may explain why inactivation of Sufu is not sufficient to induce BCC formation.
